110 related articles for article (PubMed ID: 30384811)
1. Combination of singularly perturbed vector field method and method of directly defining the inverse mapping applied to complex ODE system prostate cancer model.
Nave O; Elbaz M
J Biol Dyn; 2018 Dec; 12(1):983-1008. PubMed ID: 30384811
[TBL] [Abstract][Full Text] [Related]
2. BCG and IL - 2 model for bladder cancer treatment with fast and slow dynamics based on SPVF method-stability analysis.
Nave O; Hareli S; Elbaz M; Iluz IH; Bunimovich-Mendrazitsky S
Math Biosci Eng; 2019 Jun; 16(5):5346-5379. PubMed ID: 31499716
[TBL] [Abstract][Full Text] [Related]
3. Analysis of a breast cancer mathematical model by a new method to find an optimal protocol for HER2-positive cancer.
Nave O; Elbaz M; Bunimovich-Mendrazitsky S
Biosystems; 2020 Nov; 197():104191. PubMed ID: 32791173
[TBL] [Abstract][Full Text] [Related]
4. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
5. Targeted treatment of prostate cancer.
Wang X; Yin L; Rao P; Stein R; Harsch KM; Lee Z; Heston WD
J Cell Biochem; 2007 Oct; 102(3):571-9. PubMed ID: 17685433
[TBL] [Abstract][Full Text] [Related]
6. Asymptotic dynamics of some t-periodic one-dimensional model with application to prostate cancer immunotherapy.
Foryś U; Bodnar M; Kogan Y
J Math Biol; 2016 Oct; 73(4):867-83. PubMed ID: 26897354
[TBL] [Abstract][Full Text] [Related]
7. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
[TBL] [Abstract][Full Text] [Related]
8. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.
Rini BI; Weinberg V; Fong L; Conry S; Hershberg RM; Small EJ
Cancer; 2006 Jul; 107(1):67-74. PubMed ID: 16736512
[TBL] [Abstract][Full Text] [Related]
9. Θ-SEIHRD mathematical model of Covid19-stability analysis using fast-slow decomposition.
Nave O; Hartuv I; Shemesh U
PeerJ; 2020; 8():e10019. PubMed ID: 33005495
[TBL] [Abstract][Full Text] [Related]
10. Ordinary differential equations with applications in molecular biology.
Ilea M; Turnea M; Rotariu M
Rev Med Chir Soc Med Nat Iasi; 2012; 116(1):347-52. PubMed ID: 23077920
[TBL] [Abstract][Full Text] [Related]
11. Exploring inductive linearization for pharmacokinetic-pharmacodynamic systems of nonlinear ordinary differential equations.
Hasegawa C; Duffull SB
J Pharmacokinet Pharmacodyn; 2018 Feb; 45(1):35-47. PubMed ID: 28550375
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer.
Eaton JD; Perry MJ; Nicholson S; Guckian M; Russell N; Whelan M; Kirby RS
BJU Int; 2002 Jan; 89(1):19-26. PubMed ID: 11849155
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.
Riabov V; Tretyakova I; Alexander RB; Pushko P; Klyushnenkova EN
Vaccine; 2015 Oct; 33(41):5386-5395. PubMed ID: 26319744
[TBL] [Abstract][Full Text] [Related]
14. Dissecting the dynamics of serum prostate-specific antigen.
Vollmer RT
Am J Clin Pathol; 2010 Feb; 133(2):187-93. PubMed ID: 20093227
[TBL] [Abstract][Full Text] [Related]
15. Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial.
Antonarakis ES; Kibel AS; Yu EY; Karsh LI; Elfiky A; Shore ND; Vogelzang NJ; Corman JM; Millard FE; Maher JC; Chang NN; DeVries T; Sheikh NA; Drake CG;
Clin Cancer Res; 2017 May; 23(10):2451-2459. PubMed ID: 27836866
[No Abstract] [Full Text] [Related]
16. Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.
Saif JM; Vadakekolathu J; Rane SS; McDonald D; Ahmad M; Mathieu M; Pockley AG; Durrant L; Metheringham R; Rees RC; McArdle SE
Eur J Immunol; 2014 Apr; 44(4):994-1004. PubMed ID: 24338683
[TBL] [Abstract][Full Text] [Related]
17. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
Lubaroff DM; Karan D
Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
[TBL] [Abstract][Full Text] [Related]
18. Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization.
Kogan Y; Halevi-Tobias K; Elishmereni M; Vuk-Pavlović S; Agur Z
Cancer Res; 2012 May; 72(9):2218-27. PubMed ID: 22422938
[TBL] [Abstract][Full Text] [Related]
19. Tumor volume in prostate cancer and serum prostate-specific antigen. Analysis from a kinetic viewpoint.
Vollmer RT; Humphrey PA
Am J Clin Pathol; 2003 Jan; 119(1):80-9. PubMed ID: 12520701
[TBL] [Abstract][Full Text] [Related]
20. A partial differential equation model of metastasized prostatic cancer.
Friedman A; Jain HV
Math Biosci Eng; 2013 Jun; 10(3):591-608. PubMed ID: 23906138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
